Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
TLDR
In this article, clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma patients were evaluated using a clinical efficacy assessment.Abstract:
Multiple myeloma is the second most common hematologic malignancy Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myelomaread more
Citations
More filters
Journal ArticleDOI
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
TL;DR: Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker as mentioned in this paper .
Journal ArticleDOI
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
E Verheye,Jesús Bravo Melgar,Sofie Deschoemaeker,Geert Raes,Anke Maes,Elke De Bruyne,Eline Menu,Karin Vanderkerken,Damya Laoui,Kim De Veirman +9 more
TL;DR: This review briefly summarizes the DC development in the bone marrow niche and the phenotypical and functional characteristics of the major DC subsets, and addresses the known DC deficiencies in MM.
Journal ArticleDOI
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.
TL;DR: In this article, the authors focus on an emerging concept based on targeting CD38 to desensitize in the field of transplantation, which is based on modulation of alloimmune pathways.
Journal ArticleDOI
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
Cirino Botta,Francesco Mendicino,Enrica Antonia Martino,Ernesto Vigna,Domenica Ronchetti,Pierpaolo Correale,Fortunato Morabito,Antonino Neri,Antonino Neri,Massimo Gentile +9 more
TL;DR: In this paper, the authors describe the most recent advances in the comprehension of the role of the different cells composing the BM-IM, and discuss the potential molecular targets, which could represent new opportunities to improve current treatment strategies for MM patients.
Journal ArticleDOI
The Calcium Signaling Enzyme CD38 - A Paradigm for Membrane Topology Defining Distinct Protein Functions
TL;DR: In this article, the authors review the rationale and evidence that have led to CD38 as a paradigm for membrane topology defining distinct functions of proteins, and describe the recent discovery of a hitherto unknown cADPR-synthesizing enzyme, SARM1, ushering in a new frontier in CDPR-mediated Ca2+-signaling.
References
More filters
Journal ArticleDOI
Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage
TL;DR: It is suggested that is it now possible to define stages of T-cell differentiation that can be related to T- cell malignancies in humans.
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act,Sagar Lonial,Meletios A. Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter‑Croneck,Philippe Moreau,Maria-Victoria Mateos,Hila Magen,Andrew Belch,Donna E. Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Ka Lung Wu,Anil K. Singhal,Jesús F. San Miguel,Morio Matsumoto,Jessica Katz,Eric Bleickardt,Valerie Poulart,Kenneth C. Anderson,Paul G. Richardson +28 more
TL;DR: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death.
Related Papers (5)
Antibody-maytansinoid conjugates for the treatment of myeloma
New monoclonal antibodies on the horizon in multiple myeloma.
Elizabeth O'Donnell,Noopur Raje +1 more